Minerva Neurosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 9
- Market Cap
- $19.3M
- Introduction
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Major Depressive Disorder Pipeline Advances with 75+ Companies Developing Novel Therapies
A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.